Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B. The most common rearrangement is FIP1L1-PDGFRA (FP). The majority of patients with PDGFR-rearranged myeloproliferation respond to treatment with imatinib. In contrast to BCR-ABL-positive chronic myelogenous leukemia, only few cases of imatinib resistance and mutations of the FP kinase domain have been described so far. We hypothesized that the number of critical residues mediating imatinib resistance in FP in contrast to BCR-ABL might be limited. We performed an established systematic and comprehensive in vitro resistance screen to determine the pattern and frequency of possible TKI resistance mutations in FP. We identified 27 different FP kinase domain mutations including 25 novel variants, which attenuated response to imatinib, nilotinib or sorafenib. However, the majority of these exchanges did not confer complete inhibitor resistance. At clinically achievable drug concentrations, FP/ T674I predominated with imatinib, whereas with nilotinib and sorafenib, FP/D842V and the compound mutation T674I þ T874I became prevalent. Our results suggest that the PDGFR kinase domain contains a limited number of residues where exchanges critically interfere with binding of and inhibition by available PDGFR kinase inhibitors at achievable concentrations, which might explain the low frequency of imatinib resistance in this patient population. In addition, these findings would help to select the appropriate second-line drug in cases of imatinib-resistant disease and may be translated to other neoplasms driven by activated forms of PDGFR-A or -B.
Introduction
Idiopathic hypereosinophilic syndrome is characterized by sustained and unexplained eosinophilia exceeding 1.5 Â 10 9 per liter (Chusid et al., 1975) . A subset of patients with primary eosinophilia fall into the WHO (World Health Organization) category of myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (Cross and Reiter, 2008; Gotlib and Cools, 2008; Tefferi and Vardiman, 2008) . Myeloid neoplasms associated with rearrangements of PDGFRA, PDGFRB and FGFR1 are considered to be very rare entities (Gotlib and Cools, 2008) . The most common molecular feature is FIP1L1-PDGFRA (FP), generated by a small interstitial deletion at chromosome 4q12 (Cools et al., 2003a) . The resulting fusion gives rise to constitutive PDGFRA kinase activity and transforming potential (Cools et al., 2003a) .
The ABL, KIT and PDGFR small-molecule kinase inhibitor imatinib mesylate was reported to induce remissions in cases of idiopathic hypereosinophilic syndrome (Gleich et al., 2002) . Later, molecular responses were ascribed to expression of FP (Cools et al., 2003a) , but rapid and durable responses were also seen in myeloproliferation positive for numerous other rearrangements of PDGFR-A or -B (Cross and Reiter, 2008) . In chronic myelogenous leukemia (CML) and Ph þ ALL, clinical resistance to imatinib is associated with the emergence of point mutations within the ABL kinase domain that obviate binding of the drug. The first exchange reported was BCR-ABL/T315I (Gorre et al., 2001) , generating resistance to imatinib, nilotinib and dasatinib. In the meantime, more than 70 different BCR-ABL exchanges that confer clinical imatinib resistance have been identified in patients (Apperley, 2007) . In contrast, only seven cases of FP-positive myeloproliferation with acquired imatinib resistance due to a point mutation in the PDGFRA kinase domain have been reported so far (Cools et al., 2003a; von Bubnoff et al., 2005a; Ohnishi et al., 2006; Gotlib and Cools, 2008; Simon et al., 2008; Lierman et al., 2009; Score et al., 2009) . Strikingly, in six cases, either a FP/T674I (corresponding to T315I in cABL) or a D842V exchange of the FP kinase domain was identified, whereas in one case, a S601P þ L629P double mutation was detected (Simon et al., 2008) . Thus, we reasoned that the number of kinase domain exchanges capable of critically shifting imatinib response might be limited for FP, in contrast to BCR-ABL. We therefore aimed to generate specific resistance profiles for available PDGFR kinase inhibitors. To this end, we generated clones of FP expressing Ba/F3 cells resistant to imatinib, nilotinib and sorafenib, and show that the repertoire of strong PDGFRA resistance mutations is limited.
Results
The concentration of imatinib determines the frequency and type of FP resistance mutations With imatinib, growth of FP/wild type expressing Ba/F3 cells was suppressed with an IC50 value in the range of 2-2.5 nM. Thus, we chose 7.5-60 nM for selection. The frequency of resistant clones decreased with increasing concentrations, whereas the proportion of PDGFRA kinase domain mutated clones increased ( Figure 1a , left panel, Table 1 ). To increase the yield of mutant clones, we pretreated cells with the chemical mutagen ethylnitrosourea (Bradeen et al., 2006) and increased the imatinib concentration. At 4000 nM, which approximates to the maximum measured plasma concentration and to 1.5 times the mean trough concentration achieved in patients treated with 400 mg daily (Peng et al., 2004) , the frequency of resistant clones was 1.56 at 100 nM to 0.34 per 10 6 cells ( Figure 1a , right panel). Also, the proportion of mutant clones increased. Mutations identified with imatinib were distributed over the entire PDGFRA kinase domain (Table 1, Figure 2) . Interestingly, an F604S exchange located in the glycinerich loop (P-loop) was predominant at low imatinib concentrations and occurred mostly as compound exchange. However, at higher inhibitor concentrations, a T674I exchange became dominant (Table 1 ). This exchange recently was isolated in single cases of FPpositive myeloproliferation with clinical resistance to imatinib (Cools et al., 2003a; von Bubnoff et al., 2005a; Ohnishi et al., 2006; Gotlib and Cools, 2008) and corresponds to the gatekeeper exchange ABL/T315I identified in patients with imatinib-resistant CML (Gorre et al., 2001) . Overall, these data indicate that our assay identified FP/T674I as predominant exchange with imatinib at the concentrations achieved in the plasma of patients treated with imatinib.
With nilotinib, the profile of resistance mutations narrows to FP/D842V at therapeutic concentrations Nilotinib is active against FP (Stover et al., 2005) , and, in contrast to imatinib, has residual activity against FP/ Figure 1 Frequency of resistant clones is determined by inhibitor, drug concentration and the presence of ethylnitrosourea (ENU). Single clones of Ba/F3 cells growing in 96-well plates in the presence of imatinib (a), nilotinib (b) or sorafenib (c) were picked and analyzed for the presence of FP kinase domain mutations. Shown is the frequency of resistant clones per million cells input. Wild-type (wt, open bars) and mutant (mut, filled bars) clones are shown separately. ENU pretreatment increased the clone frequency with imatinib. Therefore, selection with nilotinib and sorafenib was performed after ENU pretreatment only. Note that with imatinib, increasing the drug concentration from 500 to 4000 nM did not further decrease the clone frequency (a), whereas with nilotinib (b) and sorafenib (c), clone frequencies decreased in a concentration-dependent manner. Figure 1b ), and steadily declined at higher concentrations. This was in contrast to imatinib, where the frequency of clones expressing T674I leveled off at the highest concentrations. Notably, at intermediate concentrations of nilotinib, the T674I gatekeeper exchange predominantly occurred as a compound mutation (Table 1) , mostly emerging with T874I (TK2, C-terminal of the A-loop). However, in marked contrast to imatinib, T674I exchanges disappeared in favor of the A-loop exchange D842V at 1000 and 2000 nM (Table 1) . Together, at clinically achievable drug concentrations nilotinib predominantly selected for FP/D842V, in contrast to FP/T674I with imatinib. Shown is the distribution of individual mutations recovered wo ENU pretreatment with imatinib at low concentrations, and after ENU treatment (+ENU) with higher concentrations of imatinib, nilotinib and sorafenib. The total number of mutant clones and the relative frequency of exchanges per condition are shown. Positions refer to human PDGFRA (NM_006206). TK1: W586 through N689; kinase insert: R690 through D789; TK2: N790 through N952.
PDGFR kinase inhibitor resistance N von Bubnoff et al
Sorafenib produces drug-resistant FP cell clones at a very low frequency The biaryl urea sorafenib is structurally distinct from imatinib and nilotinib (Supplementary Figure 7) and was shown to suppress FP/T674I (Lierman et al., 2006) . Sorafenib displayed a cellular IC50 of B0.25 nM with FP ( Figure 3c ). Compared with imatinib and nilotinib, selection with sorafenib produced a lower frequency of drug-resistant Ba/F3 clones at 200 nM, further decreasing in a concentration-dependent manner ( Figure 1c ). We were not able to obtain resistant clones at 2000 nM, which corresponds to therapeutic levels of the drug (Strumberg et al., 2005) . In 10 out of the 16 clones we obtained, seven different exchanges were identified in the PDGFRA kinase domain (Table 1) . Those in common with imatinib or nilotinib were D842V, N659Y and G610R. The remaining four exchanges came up with sorafenib only, and included A640G in (NM_002609), cKIT (X06182) and cABL (NM_005157). Highlighted in red are positions of amino-acid exchanges identified in resistant FP cell clones and corresponding variants that were found in patients with GIST (cKIT, PDGFRA) and CML (BCR-ABL). Examples include the moderately sorafenibresistant, but imatinib-sensitive FP/N659Y, which finds its counterpart in an activating, imatinib-responsive PDGFRA/N659K mutation identified in GIST (Corless et al., 2005) , and complies with FLT3-ITD/N676K, which was identified in a patient with acute myeloid leukemia (AML) and resistance to PKC412 (Heidel et al., 2006) . The weak A-loop mutation FP/Y849L matches FLT3/Y842, where an exchange to cysteine was identified as activating FLT3 mutation in AML (Kindler et al., 2005) . Different FLT3-ITD/Y842 mutations are associated with resistance to su5614 and sorafenib in vitro (von Bubnoff et al., 2009 ). An exchange of the corresponding Y823 in cKIT to aspartic acid has been identified as activating mutation associated with imatinib resistance in GIST (Heinrich et al., 2006) , and FP/V658A corresponds to cKIT/V654A, which can be found in imatinib-resistant GIST (Heinrich et al., 2006) . Figure 1) . Intriguingly only six out of the 27 exchanges that we identified displayed complete resistance to imatinib at 4000 nM (Figure 4) . Five of these highly imatinib resistant exchanges involved T674I, in line with its Figure 3 FP/D842V displays full cross-resistance, whereas the remaining exchanges respond to at least one drug at therapeutic drug concentrations. FP point mutants that were identified with imatinib, nilotinib or sorafenib including single constituents of compound mutations were recreated in FP using site-directed mutagenesis. Constructs were stably expressed in Ba/F3 cells. Proliferation was measured using (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based method after incubation for 24 and 48 h without and in the presence of inhibitors. Maximum concentrations for each compound were selected according to the clinically achievable plasma concentrations (Peng et al., 2004; Strumberg et al., 2005; Kantarjian et al., 2006) . At least two independent experiments were performed for each construct. Shown are representative results of one experiment after 48 h of incubation with imatinib (a), nilotinib (b) and sorafenib (c) for the most abundant exchanges. OD indicates optical density. Values are expressed as mean of triplicates. Bars: ± s.e. Dose-response of the remaining FP exchanges is shown in Supplementary Figures Figure 4) . However, in four out of these six highly imatinib resistant variants, nilotinib and sorafenib at therapeutic concentrations fully suppressed FP autophosphorylation and cell growth (see Figures 3 and 4 , Supplementary Figures 1-4 and Supplementary Table 1 ). In contrast, in the case of FP/T674I þ T874I, nilotinib at 2000 nM failed to completely suppress cell growth (Figure 3b) , whereas sorafenib at 1000 nM entirely blocked proliferation (Figure 3c ). This was in accordance with the predominance of T674I þ 874I over T674I with nilotinib, and its absence in sorafenibresistant cell clones (Table 1) .
In line with its abundance in clones emerging at high nilotinib concentrations, D842V led to a complete resistance to nilotinib and also to imatinib and sorafenib (Figure 3, Supplementary Table 1 ). Dasatinib recently demonstrated activity against full-length PDGFRA/ D842V (IC50 62 nM) (Dewaele et al., 2008) . In the background of FP, however, dasatinib at therapeutic concentrations only had marginal activity against D842V, and also did not display activity against T674I (Supplementary Figure 5) . In order to examine whether the presence of D842V in comparison with wild-type and other FP resistance mutations augments FP activation, we stably expressed wild type, D842V, D842H, T674I, V658A,V658G and N659Y in Ba/F3 cells. All the FP variants showed similar transformation ability and similar levels of FP autophosphorylation and STAT5 activation (Supplementary Figure 6) . These results suggest that D842V or other FP variants that were identified at high frequency do not add oncogeneic activity on the top of FP itself. Together, drug response analysis confirmed the results of our drug selection assay and suggests that, in contrast to BCR-ABL, the armory of PDGFRA kinase mutations fit enough to escape inhibition by available PDGFR kinase inhibitors is limited to T674I, compound exchanges involving T674I, and D842V.
FP/F604S complements 'weak' resistance mutations Except for the 'strong' resistance mutations involving T674I or D842V, all the remaining exchanges remained responsive to therapeutic drug levels ( Figures 3 and 4 , Supplementary Figures 1-4 There were only four exchanges that came up with sorafenib only. In accordance, two out of these four, N659Y and A640G þ N656Y, did not confer significant cross-resistance to imatinib or nilotinib, but did cause moderate sorafenib resistance (Figure 4) .
The P-loop exchange G610R identified with sorafenib and imatinib unexpectedly failed to transform Ba/F3 cells and did not show FP autophosphorylation or activation of STAT5 (data not shown), indicating that G610R compromises kinase activity, and suggesting that outgrowth of G610R-positive cell clones in the presence of imatinib or sorafenib was independent of FP kinase activity. 

Structure analysis
Drug target mutations that confer resistance weaken drug binding, enhance the oncogenicity of the drug target, or both. The drug-resistant forms described in this study fall in two distinct categories. One set of exchanges displays a similar extent of resistance to all three inhibitors (such as exchanges of V658 and N659 or D842H/V, Figure 4 ), whereas the other set retains distinct sensitivities to the three inhibitors (such as T674I or D842E/G). Retention of especially the higher sensitivity to sorafenib provides evidence that FP target is not essentially changed by the mutation. On the other hand, loss of selectivity points toward alteration of target structure or conformational equilibria away from the targeted state. The chemical structures and key interactions of the three 'type II' inhibitors of this study are shown in Supplementary Figure 7 . Type II inhibitors use the ATP binding cleft and bind the adjacent activation loop containing the conserved DFG motif being in an 'DFG out' conformation ( Figure 5 , dark blue) and additionally bind the kinase hinge ( Figure 5 , sky blue). All three inhibitors bind via aromatic-aromatic interactions with the Phe of the DFG motif, and bridge the main chain of the DFG motif ( Figure 5 , dark blue) to a conserved glutamic acid side chain from helix C (Figure 5, orange) . Sorafenib uniquely has two hydrogen bonds to the kinase hinge and three in the bridging interaction, whereas imatinib and nilotinib both have single hydrogen bonds to the hinge and two in the bridging interaction. In addition, only imatinib and nilotinib, but not sorafenib, have direct hydrogen bonds to the gatekeeper threonine. Thus, key protein target interactions of sorafenib are different from imatinib and nilotinib in PDGFR family kinases. In addition, we propose that some of the identified exchanges shift an inactive-active conformation equilibrium and thereby affect inhibitor binding. Detailed results of in silico structure modeling are presented in the supporting information.
Discussion
Both in CML and in gastrointestinal stromal tumor, acquired resistance to imatinib is associated with the emergence of secondary kinase domain mutations of the target kinase (Heinrich et al., 2006; Apperley, 2007) . More than 70 different BCR-ABL exchanges have been described that confer imatinib resistance in CML (Apperley, 2007) , including at least 10 exchanges that confer intermediate to strong imatinib resistance (O'Hare et al., 2007; Redaelli et al., 2009) . Novel ABL kinase inhibitors exhibit partially non-overlapping profiles of resistance mutations with imatinib (Azam et al., 2003; Burgess et al., 2005;  von Bubnoff et al., Figure 5 Representation of the PDGFRA mutation sites relative to the schematic fold of inactive cKIT. KIT residues are labeled according to PDGFRA mutations and numbering, from PDB code 1T46. Green shows the glycine-rich (or 'P') loop and the F604 (KIT: F600) mutation site, orange shows the a-C helix, dark blue shows the activation loop and the key D842 (KIT: D816) mutation site, light blue shows the 'molecular brake' H Â N motif loop (aC-b4 loop), and yellow highlights the P þ 1 loop and mutations. The remaining mutation positions are shown in red. The inhibitors of this study were modeled into the binding site by superposition of the cKIT-imatinib complex (1T46) with kinase domains from cABL (nilotinib, PDB code 3cs9) and BRAF (PDB codes 1uwh, 1uwj).
PDGFR kinase inhibitor resistance N von Bubnoff et al 2006b), and sequential treatment with imatinib and approved, second-generation ABL kinase inhibitors has become a reality in CML (Cortes et al., 2007) . Imatinib induces complete remissions in the majority of cases with myeloproliferation positive for PDGFRA abnormalities (Cross and Reiter, 2008) , including FP (Cools et al., 2003a) , and also for PDGFRB abnormalities, including ETV6-PDGFRB and TEL-PDGFRB (Cross and Reiter, 2008) .
It is not known whether clinical resistance to imatinib in myeloid neoplasms associated with abnormalities of PDGFRA will occur in a frequency similar to that observed in CML. Our results suggest that the repertoire of possible PDGFRA kinase domain mutations leading to a shift of drug response sufficient to cause clinical resistance to available PDGFR inhibitors at therapeutic drug levels is limited. This may be explained based on the condition that FP is 100-fold more sensitive to imatinib compared with BCR-ABL. Whether this will translate into a low frequency of clinical resistance to therapeutic PDGFR inhibition in myeloproliferation remains to be shown. To date, seven cases of FP-positive myeloproliferation and acquired imatinib resistance with a secondary mutation in the FP kinase domain have been reported. In five of these cases, drug resistance occurred in the setting of blast crisis, with a preceding 'chronic phase' reported in four cases (Cools et al., 2003a; von Bubnoff et al., 2005a; Gotlib and Cools, 2008; Lierman et al., 2009) . This is similar to CML, where imatinib resistance occurs more frequently and is more often associated with kinase domain mutations in advanced phase than in chronic phase of the disease (Baccarani et al., 2009 ). In accordance with our results, in six out of seven cases either FP/T674I or FP/D842V were identified (Cools et al., 2003a; von Bubnoff et al., 2005a; Ohnishi et al., 2006; Gotlib and Cools, 2008; Lierman et al., 2009; Score et al., 2009) , including one patient relapsing with FP/D842V and receiving treatment with sorafenib (Lierman et al., 2009) . The remaining patient was found with a S601P þ L629P double mutation (Simon et al., 2008) , which we did not identify. This or similar approaches to identify resistance mutations in kinases have been utilized with BCR-ABL and Abl kinase inhibitors, where they were demonstrated to cover most BCR-ABL mutations known from imatinib-resistant CML patients and moreover faithfully predicted most exchanges associated with resistance to nilotinib and dasatinib (Burgess et al., 2005; von Bubnoff et al., 2005b von Bubnoff et al., , 2006b Bradeen et al., 2006; Cortes et al., 2007; Branford et al., 2009; Hughes et al., 2009) . Still, it cannot be excluded that the method used failed to detect single exchanges in FP that in the future might evolve in the clinic.
In contrast to imatinib, we did not observe FP/T674I as single exchange during selection with therapeutic levels of nilotinib and sorafenib. This is in accordance with our previous observation that nilotinib suppressed FP/T674I in vitro (von Bubnoff et al., 2006a) , whereas it is not active against the corresponding exchanges BCR-ABL/T315I in CML (Gorre et al., 2001; Weisberg et al., 2005) and cKIT/T670I in gastrointestinal stromal tumor (Heinrich et al., 2006; Guo et al., 2007) . Also, sorafenib has demonstrated activity against FP/T674I in vitro (Lierman et al., 2006) . According to our structure modeling analysis, this might be explained by a lack of direct interactions between sorafenib and T674, rendering it less susceptible to exchanges at this position compared with imatinib and nilotinib. In addition to sorafenib, the staurosporine derivative PKC412 was reported to be active against FP/T674I (Cools et al., 2003b) , whereas therapeutic drug concentrations of dasatinib in our study failed to suppress FP/T674I. Consequently, nilotinib, sorafenib and PKC412 currently remain appropriate second-line treatment options for T674I after imatinib failure. Compound exchanges of FP/T674I such as FP/T674I þ T874I were not described so far, but, according to our results, might preferentially occur in patients treated with nilotinib. However, in vitro, FP/T674I compound exchanges still were sensitive to clinical concentrations of sorafenib.
In 6% of gastrointestinal stromal tumor patients, a D842V exchange in full-length PDGFRA can be identified (Corless and Heinrich, 2008) and the corresponding exchange D816V in cKIT can be found in patients with mastocytosis (Nagata et al., 1995) . Both act as activating mutations, at the same time giving rise to imatinib resistance (Ma et al., 2002; Hirota et al., 2003) , probably by destabilizing the inactive conformational state of the kinase to which imatinib binds. FP/ D842V recently has been identified in two cases of FPpositive myeloproliferation and acquired resistance to imatinib (Score et al., 2009) and sorafenib (Lierman et al., 2009) . We recovered FP/D842V with nilotinib and sorafenib, but missed this exchange with imatinib, although three other exchanges at the same position emerged with imatinib (D842E/G/H). In full-length PDGFRA, the D842V exchange was shown to cause resistance to nilotinib (Weisberg et al., 2006) , whereas PKC412, sorafenib and dasatinib had some residual activity, although at concentrations that might be above achievable plasma levels (Debiec-Rychter et al., 2005; Guida et al., 2007; Dewaele et al., 2008) . However, in FP, D842V does not respond to imatinib, nilotinib, sorafenib and dasatinib at clinically achievable levels (this work and Lierman et al., 2009) . Thus, FP/D842V in the clinic might turn out to be more critical compared with FP/T674I in terms of cross-resistance to available PDGFR kinase inhibitors.
Twenty-one out of the 27 FP exchanges that we identified in drug-resistant cell clones lead to low or intermediate resistance. Interestingly, some correspond to exchanges that were described in different oncogeneic kinases in the setting of clinical resistance to therapeutic kinase inhibition (Figure 2) . However, it has to be emphasized that exchanges mediating 'intermediate' resistance such as FP/N659Y with sorafenib might as well be relevant in the clinic, especially in patients wherein suboptimal plasma drug concentrations allow selection of such mutations. In addition, in CML it has been shown that different molecular mechanisms of resistance can act together in a synergistic manner (Lahaye et al., 2005; von Bubnoff et al., 2005b; Nicolini et al., 2007) . Consequently, switching to an alternative PDGFR inhibitor or increasing the drug dosage to achieve therapeutic drug levels might help overcome drug resistance. The availability of specific resistance profiles for each compound will facilitate clinical decision making with regard to selection of an appropriate second-or third-line agent in such cases.
In summary, our results suggest that the repertoire of possible PDGFRA kinase domain mutations leading to a 'strong' kinase inhibitor resistance is limited. It remains to be shown if this will translate into a low frequency of clinical resistance to available PDGFR inhibitors in cases of myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA.
Materials and methods
Inhibitors
Imatinib and nilotinib were kind gifts from Novartis Pharma AG, Basel, Switzerland. Sorafenib was purchased from American Chemicals Custom Corporation, San Diego, CA, USA. Dasatinib was a kind gift from Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA. Nilotinib, sorafenib and dasatinib were dissolved in dimethyl sulfoxide and imatinib was dissolved in water to make stock solutions of 10 mM.
Cell culture and DNA constructs Human FP was isolated from EOL1 cells and cloned into MSCV(Mig)-EGFP. Ba/F3 cells were obtained from the German Resource Centre for Biological Material (DSMZ) in 2005 and authenticated by DSMZ by DNA typing, species PCR and immunophenotyping (http://www.dsmz.de/human_ and_animal_cell_lines/info.php?dsmz_nr ¼ 300&term ¼ baf3& highlight ¼ ). Cells were passaged for less than 6 months and were maintained in the presence of 2 ng/ml interleukin-3 (R&D, Wiesbaden, Germany). Ba/F3 cells were transfected by electroporation and transformed upon withdrawal of interleukin-3. FP point mutations were introduced in MSCV-EGFP-FP using the QuickChange mutagenesis kit (Stratagene, Amsterdam, The Netherlands). Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). For RT-PCR of FP encompassing the fusion and the PDGFRA kinase domain, the following primers were used: FIP1L1 5 0 -ATCAAGACAGGGGGAAGAG-3 0 and PDGFRA 5 0 -CAGG CAGAGGAATGATGTAGCCAC-3 0 . The following primers were used for nested PCR: FIP1L1 5 0 -GTAGACCTTGATGC ACCTGGAAGC-3 0 and PDGFRA 5 0 -GCATTGTCTGAGT CCACACG-3 0 . For sequencing, the primers were 5 0 -CCATG GCGTAAACCTGGTGC-3 0 and 5 0 -CAGGCAGAGGAATG ATGTAGCCAC-3 0 for PDGFRA TK1 and kinase insert and 5 0 -GGGCCACATTTGAACATTGTAAAC-3 0 and 5 0 -GCAT TGTCTGAGTCCACACG-3 0 for PDGFRA TK2.
Generation of drug-resistant variants
Selection of inhibitor-resistant colonies was performed as described previously (von Bubnoff et al., 2005b) . Briefly, Ba/F3 MSCV-EGFP-FP wild-type cells were cultured in 96-well plates at a density of 4 Â 10E5 cells per well in the presence of imatinib, nilotinib or sorafenib at the indicated concentrations. Colonies that became visible were picked, expanded and analyzed. When indicated, Ba/F3 MSCV-EGFP-FP wild-type cells were pretreated with the chemical mutagene N-ethyl-N-nitrosourea (ethylnitrosourea) twice for 12 h at a concentration of 50 mg/ml (Bradeen et al., 2006) . Resistant cell clones were selected in the presence of imatinib, nilotinib and sorafenib at the indicated concentrations.
Resulting sublines were maintained in the presence of the inhibitor.
Proliferation assay and western blotting Proliferation was measured using (3-(4,5-dimethylthiazol-2-yl) -5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based method (CellTiter 96; Promega, Madison, WI, USA).
Measures were taken as triplicates after 72 and 96 h of culture without cytokines. Ba/F3 cells were cultured for 2.5 h without and in the presence of the inhibitor at the indicated concentrations. Cell lysis, SDS-PAGE and immunoblotting were done as described previously (von Bubnoff et al., 2005b) . The following antibodies were used: PDGFRA (06-495, Upstate, Millipore, Schwalbach, Germany), phosphotyrosine (4G10, Upstate; PY20, BD Transduction, BD Transduction, Heidelberg, Germany), pSTAT5 (kindly provided by Thomas T Wheeler and Henry B Sadowski, Hamilton, New Zealand), STAT5 (G-2, Santa Cruz Biotechnology, Heidelberg, Germany) and actin (A5316, Sigma-Aldrich, Taufkirchen, Germany). Bands were visualized using the enhanced chemoluminescence system (Amersham, Braunschweig, Germany).
Structure analysis
Graphical inspection and structural superposition were done with PyMOL (DeLano WL, The PyMOL Molecular Graphics System (2002), http://www.pymol.org). Individual features of inhibitor interactions and geometries were examined also using the electron density server and 3D-ligand interaction analyzer as linked in the PDB server pages.
